According to a study published in The Journal of Urology, Naturex’s proprietary full spectrum cranberry ingredient Flowens may help alleviate frequent urination, a bothersome symptom of overactive bladder in women.
Done by researchers at Weill Cornell Medicine, the randomised, double-blind placebo-controlled human clinical trial demonstrated a significant effect for Flowens in healthy women aged 18-60 over a six-month period. Women taking a daily 500mg dose of Flowens experienced two fewer daily episodes of frequent urination than those in the placebo group.
The results of the trial demonstrate the positive impact of cranberry consumption on overactive bladder (OAB) in women. OAB is not a disease but a constellation of symptoms. It’s defined by the International Continence Society as the presence of “urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of urinary tract infection or other obvious pathology.”
Emilie Fromentin PhD, Head of Explore Health, Wellness & Nutrition said: “OAB symptoms vary from slight to severe and can greatly affect a woman's quality of life. This study shows how women consuming Flowens could experience a reduction in both frequency and the sensation of urgency associated with OAB. These findings build on the positive results of a previous study that demonstrated the benefits of Flowens for reducing lower urinary tract symptoms (LUTS) in men. This latest trial provides more clear evidence of the efficacy of this proprietary ingredient when consumed to improve urinary tract health.”
Dan Souza, Global Product Manager added: “For six years now, Flowens has been helping men to improve their quality of life by reducing Low Urinary Tract Symptoms (LUTS) typically associated with prostate issues. It has full regulatory compliance and it has been awarded seven proprietary men’s health claims.
“This new study involving women widens the potential of our full spectrum cranberry product by demonstrating that it offers benefits for a further health condition that affects a completely different demographic group.”
